Leerink Swann reaffirmed their outperform rating on shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in a research note issued to investors on Wednesday morning, Marketbeat reports. The brokerage currently has a $182.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $170.00. Leerink Swann also issued estimates for Alexion Pharmaceuticals’ FY2017 earnings at $5.17 EPS. The analysts noted that the move was a valuation call.

Several other research analysts have also weighed in on ALXN. J P Morgan Chase & Co lowered Alexion Pharmaceuticals from an overweight rating to a neutral rating in a research report on Tuesday, May 23rd. Oppenheimer Holdings, Inc. reaffirmed a hold rating on shares of Alexion Pharmaceuticals in a research report on Tuesday, May 23rd. Barclays PLC reaffirmed an overweight rating and set a $155.00 price target on shares of Alexion Pharmaceuticals in a research report on Wednesday, May 24th. Stifel Nicolaus reaffirmed a buy rating and set a $157.00 price target on shares of Alexion Pharmaceuticals in a research report on Wednesday, May 24th. Finally, BMO Capital Markets reaffirmed an outperform rating and set a $158.00 price target on shares of Alexion Pharmaceuticals in a research report on Wednesday, May 24th. Five research analysts have rated the stock with a hold rating, twenty have assigned a buy rating and three have issued a strong buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of $157.13.

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 146.69 on Wednesday. Alexion Pharmaceuticals has a 12 month low of $96.18 and a 12 month high of $149.34. The firm’s 50-day moving average price is $138.83 and its 200-day moving average price is $124.75. The company has a market cap of $32.74 billion, a PE ratio of 63.61 and a beta of 1.40.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.08 by $0.48. The firm had revenue of $912.00 million for the quarter, compared to analyst estimates of $846.15 million. Alexion Pharmaceuticals had a return on equity of 7.47% and a net margin of 18.09%. The business’s quarterly revenue was up 21.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.13 EPS. Equities analysts predict that Alexion Pharmaceuticals will post $5.62 EPS for the current fiscal year.

WARNING: This piece was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/17/alexion-pharmaceuticals-alxn-outperform-rating-reiterated-at-leerink-swann.html.

In other news, Director Ann M. Veneman sold 835 shares of the company’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total transaction of $121,751.35. Following the completion of the sale, the director now directly owns 5,480 shares in the company, valued at approximately $799,038.80. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Julie O’neill sold 4,375 shares of the company’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $145.44, for a total value of $636,300.00. Following the sale, the executive vice president now owns 26,092 shares of the company’s stock, valued at $3,794,820.48. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 17,070 shares of company stock valued at $2,416,869. Corporate insiders own 4.35% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Aldebaran Financial Inc. acquired a new position in shares of Alexion Pharmaceuticals during the 2nd quarter worth $426,000. Toronto Dominion Bank raised its holdings in shares of Alexion Pharmaceuticals by 25.5% during the 2nd quarter. Toronto Dominion Bank now owns 76,071 shares of the biopharmaceutical company’s stock worth $9,254,000 after buying an additional 15,464 shares in the last quarter. WINTON GROUP Ltd acquired a new position in shares of Alexion Pharmaceuticals during the 2nd quarter worth $296,000. Public Employees Retirement System of Ohio raised its holdings in shares of Alexion Pharmaceuticals by 1.6% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 151,163 shares of the biopharmaceutical company’s stock worth $18,392,000 after buying an additional 2,394 shares in the last quarter. Finally, Wealthsource Partners LLC raised its holdings in shares of Alexion Pharmaceuticals by 4.4% during the 2nd quarter. Wealthsource Partners LLC now owns 3,002 shares of the biopharmaceutical company’s stock worth $365,000 after buying an additional 126 shares in the last quarter. 94.26% of the stock is owned by institutional investors.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.